Abstract Background Differentiating post-radiation MRI changes from progressive disease (PD) in glioblastoma (GBM) patients represents a major challenge. The clinical problem is two-sided; avoid termination of effective therapy in case of pseudoprogression (PsP) and continuation of ineffective therapy in case of PD. We retrospectively assessed incidence, management, and prognostic impact of PsP and analyzed factors associated with PsP in a GBM patient cohort. Methods Consecutive GBM patients diagnosed in South-Eastern Norway Health Region from 2015 to 2018 who had received RT and follow-up MRI were included. Tumor, patient, and treatment characteristics were analyzed in relationship to re-evaluated MRI examinations at three and six months post-radiation using Response Assessment in Neuro-Oncology criteria. Results A total of 284 patients were included in the study. PsP incidence three and six months post-radiation was 19.4% and 7.0%, respectively. In adjusted analyses, methylated O 6-methylguanine-DNA methyltransferase (MGMT) promoter and absence of neurological deterioration were associated with PsP at both three (p<0.001 and p=0.029, respectively) and six months (p=0.045 and p=0.034, respectively) post-radiation. For patients retrospectively assessed as PD three months post-radiation, there was no survival benefit of treatment change (p=0.838). Conclusion PsP incidence was similar to previous reports. In addition to the previously described correlation of methylated MGMT promoter with PsP, we also found that absence of neurological deterioration significantly correlated with PsP. Continuation of temozolomide courses did not seem to compromise survival for patients with PD at three months post-radiation; therefore, we recommend continuing adjuvant temozolomide courses in case of inconclusive MRI findings.
{"title":"Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: a cohort study","authors":"Hanne Blakstad, Eduardo Erasmo Mendoza Mireles, Liv Cathrine Heggebø, Henriette Magelssen, Mette Sprauten, Tom Børge Johannesen, Einar Vik-Mo, Henning Leske, Pitt Niehusmann, Karoline Skogen, Eirik Helseth, Kyrre Eeg Emblem, Petter Brandal","doi":"10.1093/nop/npad063","DOIUrl":"https://doi.org/10.1093/nop/npad063","url":null,"abstract":"Abstract Background Differentiating post-radiation MRI changes from progressive disease (PD) in glioblastoma (GBM) patients represents a major challenge. The clinical problem is two-sided; avoid termination of effective therapy in case of pseudoprogression (PsP) and continuation of ineffective therapy in case of PD. We retrospectively assessed incidence, management, and prognostic impact of PsP and analyzed factors associated with PsP in a GBM patient cohort. Methods Consecutive GBM patients diagnosed in South-Eastern Norway Health Region from 2015 to 2018 who had received RT and follow-up MRI were included. Tumor, patient, and treatment characteristics were analyzed in relationship to re-evaluated MRI examinations at three and six months post-radiation using Response Assessment in Neuro-Oncology criteria. Results A total of 284 patients were included in the study. PsP incidence three and six months post-radiation was 19.4% and 7.0%, respectively. In adjusted analyses, methylated O 6-methylguanine-DNA methyltransferase (MGMT) promoter and absence of neurological deterioration were associated with PsP at both three (p&lt;0.001 and p=0.029, respectively) and six months (p=0.045 and p=0.034, respectively) post-radiation. For patients retrospectively assessed as PD three months post-radiation, there was no survival benefit of treatment change (p=0.838). Conclusion PsP incidence was similar to previous reports. In addition to the previously described correlation of methylated MGMT promoter with PsP, we also found that absence of neurological deterioration significantly correlated with PsP. Continuation of temozolomide courses did not seem to compromise survival for patients with PD at three months post-radiation; therefore, we recommend continuing adjuvant temozolomide courses in case of inconclusive MRI findings.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135744647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emilie Le Rhun, Florien Boele, Giuseppe Minniti, Norbert Galldiks, Martin Taphoorn, Karin Piil, Roberta Rudà, Simone P Niclou, Marjolein Geurts, Matthias Preusser, Michael Weller, Susan C Short, Linda Dirven
Abstract Background The proportion of women among healthcare and biomedical research professionals in neuro-oncology is growing. With changes in cultural expectations and work-life balance considerations, more men aspire to nonfull-time jobs, yet, leadership positions remain dominated by men. Methods The European Association of Neuro-Oncology (EANO) disparity committee carried out a digital survey to explore gender balance and actions suitable to promote gender equality. The survey was distributed among EANO members in 2021, with responses analyzed descriptively. Results In total, 262 participants completed the survey (141 women, 53.8%; median age 43). Respondents were neurosurgeons (68, 26.0%); neurologists (67, 25.6%), medical oncologists (43, 16.4%), or other healthcare or research professionals; 208 participants (79.4%) worked full-time. Positive action to enforce the role of women in neuro-oncology was deemed necessary by 180 participants (68.7%), but only 28 participants (10.7%) agreed that women only should be promoted until gender balance is reached. A majority of respondents (162, 61.8%) felt that women with an equivalent CV should be prioritized over men to reach gender balance. If in the future the balance favored women at higher positions, 112 respondents (42.7%) agreed to apply positive action for men. The top indicators considered relevant to measure gender balance were: salary for similar positions (183/228, 80.3%), paid overtime (176/228, 77.2%), number of permanent positions (164/228, 71.9%), protected time for research (161/227, 70.9%), and training opportunities (157/227, 69.2%). Conclusions Specific indicators may help to measure and promote gender balance and should be considered for implementation among healthcare professionals in neuro-oncology.
{"title":"Gender balance and suitable positive actions to promote gender equality among health care professionals in neuro-oncology: the EANO positive action initiative","authors":"Emilie Le Rhun, Florien Boele, Giuseppe Minniti, Norbert Galldiks, Martin Taphoorn, Karin Piil, Roberta Rudà, Simone P Niclou, Marjolein Geurts, Matthias Preusser, Michael Weller, Susan C Short, Linda Dirven","doi":"10.1093/nop/npad064","DOIUrl":"https://doi.org/10.1093/nop/npad064","url":null,"abstract":"Abstract Background The proportion of women among healthcare and biomedical research professionals in neuro-oncology is growing. With changes in cultural expectations and work-life balance considerations, more men aspire to nonfull-time jobs, yet, leadership positions remain dominated by men. Methods The European Association of Neuro-Oncology (EANO) disparity committee carried out a digital survey to explore gender balance and actions suitable to promote gender equality. The survey was distributed among EANO members in 2021, with responses analyzed descriptively. Results In total, 262 participants completed the survey (141 women, 53.8%; median age 43). Respondents were neurosurgeons (68, 26.0%); neurologists (67, 25.6%), medical oncologists (43, 16.4%), or other healthcare or research professionals; 208 participants (79.4%) worked full-time. Positive action to enforce the role of women in neuro-oncology was deemed necessary by 180 participants (68.7%), but only 28 participants (10.7%) agreed that women only should be promoted until gender balance is reached. A majority of respondents (162, 61.8%) felt that women with an equivalent CV should be prioritized over men to reach gender balance. If in the future the balance favored women at higher positions, 112 respondents (42.7%) agreed to apply positive action for men. The top indicators considered relevant to measure gender balance were: salary for similar positions (183/228, 80.3%), paid overtime (176/228, 77.2%), number of permanent positions (164/228, 71.9%), protected time for research (161/227, 70.9%), and training opportunities (157/227, 69.2%). Conclusions Specific indicators may help to measure and promote gender balance and should be considered for implementation among healthcare professionals in neuro-oncology.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"204 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135744891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abstract Background Optic nerve sheath meningiomas (ONSM) are rare tumors potentially causing visual deficits. This study aims to report the anatomic and visual outcomes of patients with primary ONSM treated with hypofractionated stereotactic radiotherapy (HF-SRT). Methods Data of 36 patients treated with HF-SRT between 2008 and 2019 were retrospectively collected. The clinical target volume (CTV) was equal to the gross tumor volume and a 2 mm was added for the planning target volume. All responses other than progression were accepted as local control (LC). The VA grading was performed under 3 groups to provide an even distribution; 20/400 or worse, 20/40-20/400, and 20/40 or better. Results Median HF-SRT dose was 25 Gy and the median CTV was 1.94 cc. After a median of 106 months of follow-up, the tumor regressed in 23 (64%), was stable in 9 (25%), and progressed in 4 (11%) eyes. The overall rate of LC was 89% with 2-, 5-, 10-, and 15-year rate of 100%, 94%, 84%, and 84%, respectively. Treatment-related late toxicity rate was 11%. The VA was stable in 27 (75%) eyes, improved in 5 (14%) eyes, and worsened in 4 (11%) eyes, respectively, after HF-SRT. Female gender was the only independent predictor of an improved VA. Conclusions Hypofractionated stereotactic radiotherapy is a safe and satisfactory treatment option for primary ONSM without severe toxicity. It may be advisable to commence treatment before an established visual deficit of 20/400 or worse occurs, to make the most of the functional benefit.
{"title":"Role of Hypofractionated Stereotactic Radiotherapy for Primary Optic Nerve Sheath Meningioma","authors":"İrem Koç, Sezin Yüce Sarı, Gözde Yazıcı, Yasemin Kapucu, Hayyam Kıratlı, Faruk Zorlu","doi":"10.1093/nop/npad060","DOIUrl":"https://doi.org/10.1093/nop/npad060","url":null,"abstract":"Abstract Background Optic nerve sheath meningiomas (ONSM) are rare tumors potentially causing visual deficits. This study aims to report the anatomic and visual outcomes of patients with primary ONSM treated with hypofractionated stereotactic radiotherapy (HF-SRT). Methods Data of 36 patients treated with HF-SRT between 2008 and 2019 were retrospectively collected. The clinical target volume (CTV) was equal to the gross tumor volume and a 2 mm was added for the planning target volume. All responses other than progression were accepted as local control (LC). The VA grading was performed under 3 groups to provide an even distribution; 20/400 or worse, 20/40-20/400, and 20/40 or better. Results Median HF-SRT dose was 25 Gy and the median CTV was 1.94 cc. After a median of 106 months of follow-up, the tumor regressed in 23 (64%), was stable in 9 (25%), and progressed in 4 (11%) eyes. The overall rate of LC was 89% with 2-, 5-, 10-, and 15-year rate of 100%, 94%, 84%, and 84%, respectively. Treatment-related late toxicity rate was 11%. The VA was stable in 27 (75%) eyes, improved in 5 (14%) eyes, and worsened in 4 (11%) eyes, respectively, after HF-SRT. Female gender was the only independent predictor of an improved VA. Conclusions Hypofractionated stereotactic radiotherapy is a safe and satisfactory treatment option for primary ONSM without severe toxicity. It may be advisable to commence treatment before an established visual deficit of 20/400 or worse occurs, to make the most of the functional benefit.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135689992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mackenzie Price, Katherine Ryan, Madison L Shoaf, Corey Neff, J Bryan Iorgulescu, Daniel B Landi, Gino Cioffi, Kristin A Waite, Carol Kruchko, Jill S Barnholtz-Sloan, Quinn T Ostrom
Abstract Background The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-based data for primary brain and other central nervous system (CNS) in the US. CBTRUS publishes an annual statistical report which provides critical reference data for the broad neuro-oncology community. Here we summarize the key findings from the 2022 CBTRUS annual statistical report for healthcare providers. Methods Incidence data were obtained from the CDC’s National Program of Cancer Registries (NPCR) and NCI’s Surveillance, Epidemiology, and End Results Program for 52 central cancer registries (CCRs). Survival data were obtained from 42 NPCR CCRs. All rates are per 100,000 and age-adjusted using the 2000 US standard population. Overall median survival was estimated using Kaplan-Meier models. Survival data for selected molecularly-defined histopathologies are from the National Cancer Database. Mortality data are from the National Vital Statistics System. Results The average annual age-adjusted incidence rate of all primary brain and other CNS tumors was 24.25/100,000. Incidence was higher in females and non-Hispanics. The most commonly occurring malignant and predominately non-malignant tumors was glioblastoma (14% of all primary brain tumors) and meningioma (39% of all primary brain tumors), respectively. Mortality rates and overall median survival varied by age, sex, and histopathology. Conclusions This summary describes the most up-to-date population-based incidence, mortality, and survival, of primary brain and other CNS tumors in the US, and aims to serve as a concise resource for neuro-oncology providers.
{"title":"Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015-2019","authors":"Mackenzie Price, Katherine Ryan, Madison L Shoaf, Corey Neff, J Bryan Iorgulescu, Daniel B Landi, Gino Cioffi, Kristin A Waite, Carol Kruchko, Jill S Barnholtz-Sloan, Quinn T Ostrom","doi":"10.1093/nop/npad061","DOIUrl":"https://doi.org/10.1093/nop/npad061","url":null,"abstract":"Abstract Background The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-based data for primary brain and other central nervous system (CNS) in the US. CBTRUS publishes an annual statistical report which provides critical reference data for the broad neuro-oncology community. Here we summarize the key findings from the 2022 CBTRUS annual statistical report for healthcare providers. Methods Incidence data were obtained from the CDC’s National Program of Cancer Registries (NPCR) and NCI’s Surveillance, Epidemiology, and End Results Program for 52 central cancer registries (CCRs). Survival data were obtained from 42 NPCR CCRs. All rates are per 100,000 and age-adjusted using the 2000 US standard population. Overall median survival was estimated using Kaplan-Meier models. Survival data for selected molecularly-defined histopathologies are from the National Cancer Database. Mortality data are from the National Vital Statistics System. Results The average annual age-adjusted incidence rate of all primary brain and other CNS tumors was 24.25/100,000. Incidence was higher in females and non-Hispanics. The most commonly occurring malignant and predominately non-malignant tumors was glioblastoma (14% of all primary brain tumors) and meningioma (39% of all primary brain tumors), respectively. Mortality rates and overall median survival varied by age, sex, and histopathology. Conclusions This summary describes the most up-to-date population-based incidence, mortality, and survival, of primary brain and other CNS tumors in the US, and aims to serve as a concise resource for neuro-oncology providers.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135425445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julia K Brechbiel, Kelcie D Willis, Morgan P Reid, Autumn Lanoye, Farah J Aslanzadeh, Amber M Fox, Sarah Ellen Braun, Ashlee R Loughan
Abstract Background Post-traumatic growth (PTG) has been extensively explored within general oncology, yet little is known about the experience of PTG in neuro-oncology. This study aimed to determine the representation of patients with primary brain tumors (PBT) in the PTG literature. Methods PsycINFO, PubMed, and CINAHL were systematically searched from inception to December 2022. Search terms were related to personal growth and positive reactions to cancer. Articles were first screened by titles and abstracts, then full texts were reviewed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses method. Results A total of 382 articles met the inclusion criteria. Of those, 13 included patients with PBT. Over 100 000 cancer patients were represented, with 0.79% having a PBT. Most research focused on low-grade gliomas. PTG negatively correlated with post-traumatic stress symptoms and avoidant coping. In the sole longitudinal study, patients with PBT demonstrated improved PTG after 1 year. Three quasi-experimental studies investigated the effect of mindfulness-based interventions with mixed-cancer samples and demonstrated improvement in PTG. Conclusions The inclusion rate of patients with PBT in the PTG literature was significantly lower than the population prevalence rate (1.3% of cancer diagnoses). Relatively few studies focused exclusively on how patients with PBT experience PTG (k = 5), and those that did only included low-grade glioma. The experience of PTG in those with high-grade glioma remains unknown. Patients with PBT are scarcely included in research on PTG interventions. Few studies examined the relationship between PTG and medical, cognitive, or psychological characteristics. Our understanding of the PTG experience in neuro-oncology remains extremely limited.
{"title":"Primary brain tumor representation in the post-traumatic growth literature: A scoping review","authors":"Julia K Brechbiel, Kelcie D Willis, Morgan P Reid, Autumn Lanoye, Farah J Aslanzadeh, Amber M Fox, Sarah Ellen Braun, Ashlee R Loughan","doi":"10.1093/nop/npad058","DOIUrl":"https://doi.org/10.1093/nop/npad058","url":null,"abstract":"Abstract Background Post-traumatic growth (PTG) has been extensively explored within general oncology, yet little is known about the experience of PTG in neuro-oncology. This study aimed to determine the representation of patients with primary brain tumors (PBT) in the PTG literature. Methods PsycINFO, PubMed, and CINAHL were systematically searched from inception to December 2022. Search terms were related to personal growth and positive reactions to cancer. Articles were first screened by titles and abstracts, then full texts were reviewed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses method. Results A total of 382 articles met the inclusion criteria. Of those, 13 included patients with PBT. Over 100 000 cancer patients were represented, with 0.79% having a PBT. Most research focused on low-grade gliomas. PTG negatively correlated with post-traumatic stress symptoms and avoidant coping. In the sole longitudinal study, patients with PBT demonstrated improved PTG after 1 year. Three quasi-experimental studies investigated the effect of mindfulness-based interventions with mixed-cancer samples and demonstrated improvement in PTG. Conclusions The inclusion rate of patients with PBT in the PTG literature was significantly lower than the population prevalence rate (1.3% of cancer diagnoses). Relatively few studies focused exclusively on how patients with PBT experience PTG (k = 5), and those that did only included low-grade glioma. The experience of PTG in those with high-grade glioma remains unknown. Patients with PBT are scarcely included in research on PTG interventions. Few studies examined the relationship between PTG and medical, cognitive, or psychological characteristics. Our understanding of the PTG experience in neuro-oncology remains extremely limited.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135060809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kyle R Noll, Priscella Asman, Israt Tasnim, Matthew Hall, Katherine Connelly, Chandra Swamy, Chibawanye Ene, Sudhakar Tummala, Roxana M Grasu, Ho-Ling Liu, Vinodh A Kumar, Matthew Muir, Sarah Prinsloo, Hayley Michener, Jeffrey S Wefel, Nuri F Ince, Sujit S Prabhu
Abstract Background Electrocorticography (ECoG) language mapping is often performed extraoperatively, frequently involves offline processing, and relationships with direct cortical stimulation (DCS) remain variable. We sought to determine the feasibility and preliminary utility of an intraoperative language mapping approach guided by real-time visualization of electrocorticograms. Methods A patient with astrocytoma underwent awake craniotomy with intraoperative language mapping, utilizing a dual iPad stimulus presentation system coupled to a real-time neural signal processing platform capable of both ECoG recording and delivery of DCS. Gamma band modulations in response to 4 language tasks at each electrode were visualized in real-time. Next, DCS was conducted for each neighboring electrode pair during language tasks. Results All language tasks resulted in strongest heat map activation at an electrode pair in the anterior to mid superior temporal gyrus. Consistent speech arrest during DCS was observed for Object and Action naming tasks at these same electrodes, indicating good correspondence with ECoG heat map recordings. This region corresponded well with posterior language representation via preoperative functional MRI. Conclusions Intraoperative real-time visualization of language task-based ECoG gamma band modulation is feasible and may help identify targets for DCS. If validated, this may improve the efficiency and accuracy of intraoperative language mapping.
{"title":"Intraoperative language mapping guided by real-time visualization of gamma band modulation electrocorticograms: case report and proof of concept","authors":"Kyle R Noll, Priscella Asman, Israt Tasnim, Matthew Hall, Katherine Connelly, Chandra Swamy, Chibawanye Ene, Sudhakar Tummala, Roxana M Grasu, Ho-Ling Liu, Vinodh A Kumar, Matthew Muir, Sarah Prinsloo, Hayley Michener, Jeffrey S Wefel, Nuri F Ince, Sujit S Prabhu","doi":"10.1093/nop/npad059","DOIUrl":"https://doi.org/10.1093/nop/npad059","url":null,"abstract":"Abstract Background Electrocorticography (ECoG) language mapping is often performed extraoperatively, frequently involves offline processing, and relationships with direct cortical stimulation (DCS) remain variable. We sought to determine the feasibility and preliminary utility of an intraoperative language mapping approach guided by real-time visualization of electrocorticograms. Methods A patient with astrocytoma underwent awake craniotomy with intraoperative language mapping, utilizing a dual iPad stimulus presentation system coupled to a real-time neural signal processing platform capable of both ECoG recording and delivery of DCS. Gamma band modulations in response to 4 language tasks at each electrode were visualized in real-time. Next, DCS was conducted for each neighboring electrode pair during language tasks. Results All language tasks resulted in strongest heat map activation at an electrode pair in the anterior to mid superior temporal gyrus. Consistent speech arrest during DCS was observed for Object and Action naming tasks at these same electrodes, indicating good correspondence with ECoG heat map recordings. This region corresponded well with posterior language representation via preoperative functional MRI. Conclusions Intraoperative real-time visualization of language task-based ECoG gamma band modulation is feasible and may help identify targets for DCS. If validated, this may improve the efficiency and accuracy of intraoperative language mapping.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135203167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal Article Forthcoming Meetings Get access Jennie W Taylor Jennie W Taylor Search for other works by this author on: Oxford Academic Google Scholar Neuro-Oncology Practice, Volume 10, Issue 5, October 2023, Page 495, https://doi.org/10.1093/nop/npad052 Published: 15 September 2023 Article history Corrected and typeset: 15 September 2023 Published: 15 September 2023
期刊文章即将召开的会议获取访问Jennie W Taylor Jennie W Taylor搜索作者的其他作品:牛津学术谷歌学者神经肿瘤学实践，第10卷，第5期，2023年10月，第495页，https://doi.org/10.1093/nop/npad052出版:2023年9月15日文章历史更正和排版:2023年9月15日出版:2023年9月15日
{"title":"Forthcoming Meetings","authors":"Jennie W Taylor","doi":"10.1093/nop/npad052","DOIUrl":"https://doi.org/10.1093/nop/npad052","url":null,"abstract":"Journal Article Forthcoming Meetings Get access Jennie W Taylor Jennie W Taylor Search for other works by this author on: Oxford Academic Google Scholar Neuro-Oncology Practice, Volume 10, Issue 5, October 2023, Page 495, https://doi.org/10.1093/nop/npad052 Published: 15 September 2023 Article history Corrected and typeset: 15 September 2023 Published: 15 September 2023","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135395584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Han Choi, Amr S Soliman, Randa Al Mousa, Jennifer Yeh, Jamal Khader, Iyad Sultan, Ahmad K H Ibrahimi
Abstract Background The number of cancer survivors and survivorship are increasing. Health-related quality of life (HRQOL) has not been widely studied in low-and-middle-income countries (LMICs). The aim of this study is to explore HRQOL of childhood brain tumor survivors and its determinants in Jordan. Methods Health-related quality of life information was collected from 80 patients treated at the King Hussein Cancer Center and their parents using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales questionnaire in Arabic. Multivariable linear OLS regression models were used to analyze correlates of HRQOL and compare differences between child- and parent-reported responses. Results Health-related quality of life scores reported by survivors and by parents were positively correlated on all subscales and total PedsQL scores (r = 0.59, P = .001). Survivors reported better HRQOL in cognitive subscale (β = 0.56, P = .03) and worse HRQOL in work subscale (β = 0.43, P = .04), but no significant differences in the physical, emotional, and social subscales and total PedsQL scores. Significant predictors of HRQOL reported by parents and by children were different. Supratentorial tumor location was associated with a 10.97-unit lower physical HRQOL score, and recurrence of tumors predicted a 17.5-unit lower total HRQOL score, indicating worse quality of life. Male gender (β = 14.9, P = .002) and diagnosis of hypopituitarism (β = 16.1, P = .03) were associated with better HRQOL. Furthermore, patients that only had radiotherapy treatment had better emotional HRQOL (β = 32.9, P = .006) compared to patients that had combined radiotherapy and chemotherapy. Conclusion This study provides evidence on determinants of HRQOL of pediatric brain tumor patients in Jordan. Future studies need to capitalize on the findings of this study to institute a system for regular assessment of quality of life of pediatric cancer patients in Jordan and other countries with similar health care systems and sociocultural backgrounds.
摘要背景癌症幸存者的数量和生存率都在不断增加。与健康相关的生活质量(HRQOL)尚未在低收入和中等收入国家(LMICs)得到广泛研究。本研究的目的是探讨约旦儿童脑肿瘤幸存者的HRQOL及其决定因素。方法采用阿拉伯语儿科生活质量量表(PedsQL)通用核心量表，收集侯赛因国王癌症中心治疗的80例患者及其父母的健康相关生活质量信息。使用多变量线性OLS回归模型分析HRQOL的相关因素，并比较儿童和父母报告的反应之间的差异。结果幸存者和父母报告的健康相关生活质量评分在所有子量表和PedsQL总分上均呈正相关(r = 0.59, P = 0.001)。幸存者在认知亚量表中HRQOL较好(β = 0.56, P = 0.03)，在工作亚量表中HRQOL较差(β = 0.43, P = 0.04)，但在身体、情感和社会亚量表以及PedsQL总分上无显著差异。父母和孩子报告的HRQOL的显著预测因子存在差异。幕上肿瘤位置与物理HRQOL评分降低10.97个单位相关，肿瘤复发预测总HRQOL评分降低17.5个单位，表明生活质量较差。男性(β = 14.9, P = 0.002)和垂体功能减退(β = 16.1, P = 0.03)与较好的HRQOL相关。此外，单纯放疗患者的情绪HRQOL优于放化疗患者(β = 32.9, P = 0.006)。结论本研究为约旦儿童脑肿瘤患者HRQOL的影响因素提供了证据。未来的研究需要利用这项研究的结果，建立一个定期评估约旦和其他具有类似卫生保健系统和社会文化背景的国家儿童癌症患者生活质量的系统。
{"title":"Health-related Quality of Life of Pediatric Brain Tumor Survivors after Treatment in Jordan","authors":"Han Choi, Amr S Soliman, Randa Al Mousa, Jennifer Yeh, Jamal Khader, Iyad Sultan, Ahmad K H Ibrahimi","doi":"10.1093/nop/npad054","DOIUrl":"https://doi.org/10.1093/nop/npad054","url":null,"abstract":"Abstract Background The number of cancer survivors and survivorship are increasing. Health-related quality of life (HRQOL) has not been widely studied in low-and-middle-income countries (LMICs). The aim of this study is to explore HRQOL of childhood brain tumor survivors and its determinants in Jordan. Methods Health-related quality of life information was collected from 80 patients treated at the King Hussein Cancer Center and their parents using the Pediatric Quality of Life Inventory (PedsQL) Generic Core Scales questionnaire in Arabic. Multivariable linear OLS regression models were used to analyze correlates of HRQOL and compare differences between child- and parent-reported responses. Results Health-related quality of life scores reported by survivors and by parents were positively correlated on all subscales and total PedsQL scores (r = 0.59, P = .001). Survivors reported better HRQOL in cognitive subscale (β = 0.56, P = .03) and worse HRQOL in work subscale (β = 0.43, P = .04), but no significant differences in the physical, emotional, and social subscales and total PedsQL scores. Significant predictors of HRQOL reported by parents and by children were different. Supratentorial tumor location was associated with a 10.97-unit lower physical HRQOL score, and recurrence of tumors predicted a 17.5-unit lower total HRQOL score, indicating worse quality of life. Male gender (β = 14.9, P = .002) and diagnosis of hypopituitarism (β = 16.1, P = .03) were associated with better HRQOL. Furthermore, patients that only had radiotherapy treatment had better emotional HRQOL (β = 32.9, P = .006) compared to patients that had combined radiotherapy and chemotherapy. Conclusion This study provides evidence on determinants of HRQOL of pediatric brain tumor patients in Jordan. Future studies need to capitalize on the findings of this study to institute a system for regular assessment of quality of life of pediatric cancer patients in Jordan and other countries with similar health care systems and sociocultural backgrounds.","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135830584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-30eCollection Date: 2023-10-01DOI: 10.1093/nop/npad043
M Gorter, J G Röttgering, V Belgers, P C De Witt Hamer, L Douw, M Klein
{"title":"Letter regarding \"Acceptability and feasibility of neurocognitive assessments with adults with primary brain cancer and brain metastasis: A systematic review\".","authors":"M Gorter, J G Röttgering, V Belgers, P C De Witt Hamer, L Douw, M Klein","doi":"10.1093/nop/npad043","DOIUrl":"10.1093/nop/npad043","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 5","pages":"491-492"},"PeriodicalIF":2.4,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10360907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis
Journal Article Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.” Get access Evangelia Liouta, Evangelia Liouta Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery LaboratoryHellenic Center for Neurosurgical Research “Prof. Petros Kokkalis”, Athens, Greece Corresponding Author: Evangelia Liouta, PhD, Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece, Hellenic Center for Neurosurgical Research “Prof. Petros Kokkalis,” Athens, Greece (evangelialiouta286@hotmail.com). https://orcid.org/0000-0003-2948-9631 Search for other works by this author on: Oxford Academic Google Scholar Aristotelis V Kalyvas, Aristotelis V Kalyvas Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceDivision of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada https://orcid.org/0000-0002-0222-488X Search for other works by this author on: Oxford Academic Google Scholar Spyridon Komaitis, Spyridon Komaitis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-7250-414X Search for other works by this author on: Oxford Academic Google Scholar Evangelos Drosos, Evangelos Drosos Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-0456-7317 Search for other works by this author on: Oxford Academic Google Scholar Christos Koutsarnakis, Christos Koutsarnakis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-1363-5385 Search for other works by this author on: Oxford Academic Google Scholar Juan M García-Gómez, Juan M García-Gómez Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Javier Juan-Albarracín, Javier Juan-Albarracín Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Vasileios Katsaros, Vasileios Katsaros Department of Radiology, General Anti-Cancer and Oncological Hospital of Athens “St. Savvas,” Athens, Greece https://orcid.org/0000-0003-3087-1475 Search for ot
期刊文章对“评估高级别胶质瘤术前神经认知状态和IDH1突变状态之间的关系:对潜在混杂变量的深入研究”信函的回应。访问Evangelia Liouta, Evangelia Liouta神经外科，雅典国立和卡波distrian大学，Evangelismos医院，希腊雅典雅典微神经外科实验室，希腊神经外科研究中心“Prof. Petros Kokkalis”，希腊雅典Evangelia Liouta，博士，神经外科，雅典国立和Kapodistrian大学，Evangelismos医院，希腊雅典，希腊神经外科研究中心Petros Kokkalis教授，希腊雅典(evangelialiouta286@hotmail.com)。https://orcid.org/0000-0003-2948-9631搜索作者的其他作品:牛津学术谷歌学者Aristotelis V Kalyvas, Aristotelis V Kalyvas神经外科，雅典国立和卡波迪斯大学，希腊雅典Evangelismos医院神经外科，多伦多西部医院，大学健康网络，多伦多大学，多伦多，on，加拿大https://orcid.org/0000-0002-0222-488X搜索作者的其他作品:牛津学术谷歌学者Spyridon Komaitis, Spyridon Komaitis神经外科，雅典国立和Kapodistrian大学，Evangelismos医院，雅典微神经外科实验室https://orcid.org/0000-0002-7250-414X搜索作者的其他作品:牛津学术谷歌学者Evangelos Drosos, Evangelos Drosos神经外科，雅典国立和卡波迪兰大学，Evangelismos医院，雅典，希腊雅典微神经外科实验室https://orcid.org/0000-0002-0456-7317搜索作者的其他作品:牛津学术谷歌学者Christos Koutsarnakis, Christos Koutsarnakis神经外科，雅典国立和卡波迪斯特大学，Evangelismos医院，希腊雅典微神经外科实验室https://orcid.org/0000-0002-1363-5385牛津大学学术谷歌学者Juan M García-Gómez, Juan M García-Gómez西班牙巴伦西亚瓦伦西亚政治大学(Universitat politicnica de val ncia)， las应用研究所Tecnologías de la Información y de las communicaciones Avanzadas (ITACA)， Informática biomdica (IBIME)牛津大学学术谷歌学者Javier Juan-Albarracín, Javier Juan-Albarracín西班牙巴伦西亚瓦伦西亚政治大学应用研究所Tecnologías de la Información y de las communicaciones Avanzadas (ITACA) Informática biomacimica (IBIME)牛津学术谷歌学者Vasileios Katsaros, Vasileios Katsaros放射科，雅典“圣萨瓦斯”抗癌和肿瘤医院，希腊雅典https://orcid.org/0000-0003-3087-1475搜索作者的其他作品:牛津学术谷歌学者Theodosis Kalamatianos, Theodosis Kalamatianos神经外科，雅典国立和卡波迪斯特兰大学，Evangelismos医院，雅典，希腊雅典希腊神经外科研究中心“Prof. Petros Kokkalis”，希腊雅典https://orcid.org/0000-0003-4634-2965牛津学术谷歌学者Theodoros Argyrakos, Theodoros Argyrakos病理学部，福音医院，雅典，希腊搜索作者的其他作品:牛津学术谷歌学者…显示更多乔治·斯特兰加里斯乔治·斯特兰加里斯神经外科，雅典国立和卡波迪兰大学，Evangelismos医院，希腊雅典雅典微神经外科实验室，希腊神经外科研究中心“教授Petros Kokkalis”，希腊雅典https://orcid.org/0000-0002-9556-0101搜索作者的其他作品:牛津学术谷歌学者神经肿瘤学实践，npad045, https://doi.org/10.1093/nop/npad045出版:2023年8月25日
{"title":"Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.”","authors":"Evangelia Liouta, Aristotelis V Kalyvas, Spyridon Komaitis, Evangelos Drosos, Christos Koutsarnakis, Juan M García-Gómez, Javier Juan-Albarracín, Vasileios Katsaros, Theodosis Kalamatianos, Theodoros Argyrakos, George Stranjalis","doi":"10.1093/nop/npad045","DOIUrl":"https://doi.org/10.1093/nop/npad045","url":null,"abstract":"Journal Article Response to letter regarding “Assessing the association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas: A deeper look into potential confounding variables.” Get access Evangelia Liouta, Evangelia Liouta Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery LaboratoryHellenic Center for Neurosurgical Research “Prof. Petros Kokkalis”, Athens, Greece Corresponding Author: Evangelia Liouta, PhD, Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece, Hellenic Center for Neurosurgical Research “Prof. Petros Kokkalis,” Athens, Greece (evangelialiouta286@hotmail.com). https://orcid.org/0000-0003-2948-9631 Search for other works by this author on: Oxford Academic Google Scholar Aristotelis V Kalyvas, Aristotelis V Kalyvas Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceDivision of Neurosurgery, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada https://orcid.org/0000-0002-0222-488X Search for other works by this author on: Oxford Academic Google Scholar Spyridon Komaitis, Spyridon Komaitis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-7250-414X Search for other works by this author on: Oxford Academic Google Scholar Evangelos Drosos, Evangelos Drosos Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-0456-7317 Search for other works by this author on: Oxford Academic Google Scholar Christos Koutsarnakis, Christos Koutsarnakis Department of Neurosurgery, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, GreeceAthens Microneurosurgery Laboratory https://orcid.org/0000-0002-1363-5385 Search for other works by this author on: Oxford Academic Google Scholar Juan M García-Gómez, Juan M García-Gómez Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Javier Juan-Albarracín, Javier Juan-Albarracín Grupo de Informática Biomédica (IBIME), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València, Valencia, Spain Search for other works by this author on: Oxford Academic Google Scholar Vasileios Katsaros, Vasileios Katsaros Department of Radiology, General Anti-Cancer and Oncological Hospital of Athens “St. Savvas,” Athens, Greece https://orcid.org/0000-0003-3087-1475 Search for ot","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135285641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：